ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ARTLW Artelo Biosciences Inc

0.01
-0.00101 (-9.13%)
After Hours
Last Updated: 16:00:02
Delayed by 15 minutes

Period:

Draw Mode:

Volume 700
Bid Price 0.0001
Ask Price 2,147.48
News -
Company Name Stock Ticker Symbol Market Type
Artelo Biosciences Inc ARTLW NASDAQ Equity Warrant
  Price Change Change Percent Stock Price Last Traded
-0.00101 -9.13% 0.01 16:00:02
Open Price Low Price High Price Close Price Prev Close
0.01 0.01 0.01 0.01 0.011005
Trades Volume VWAP Dollar Volume Avg Volume
3 700  0.01  7 -
Last Trade Time Type Quantity Stock Price Currency
16:00:00 646  0.01 USD

Artelo Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.82M 3.19M - 0 -9.29M -2.91 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Artelo Biosciences

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ARTLW Message Board. Create One! See More Posts on ARTLW Message Board See More Message Board Posts

ARTLW Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approaches to cannabinoid-based therapies, including those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds that promote the effectiveness of the endocannabinoid system. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

Your Recent History

Delayed Upgrade Clock